Heyuan Biotechnology Valuation, Funding & Investors

Heyuan Biotechnology is valued at $3B as of June 2020.

Last Heyuan Biotechnology valuation

$3B

Series C · Jun 2020

Last Heyuan Biotechnology funding round

$300M

Series C · Jun 2020

Cumulative funding Heyuan Biotechnology raised

$300M

across 1 funding round

Key investors in Heyuan Biotechnology

  • Morningside
  • Loyal Valley Capital
  • Boyuan Capital
  • Kunlun Capital
  • Jinpu Investment
  • Sherpa Capital

Heyuan Biotechnology Overview

About Heyuan Biotechnology

Heyuan Biotechnology is a Chinese provider of gene therapy services, specializing in AAV and lentiviral vector production, CRISPR-based gene editing, and in vivo efficacy testing. Operating from facilities certified under ISO 13485, it supports pharma clients with plasmid design, viral packaging at titers exceeding 10^13 vg/mL, and animal model studies for CNS and oncology targets.


Founded

2013

HQ

ChinaShanghai

Status

Privately held

Customer focus

B2B

Revenue model

Services

Valuation

$3B (Jun 2020)

Heyuan Biotechnology Valuation

Heyuan Biotechnology is currently valued at $3B, based on its Series C in June 2020.

The $300M round was led by Loyal Valley Capital, with participation from Kunlun Capital, Jinpu Investment, Sherpa Capital, Morningside and Boyuan Capital.

Heyuan Biotechnology valuation by funding round

Heyuan Biotechnology valuation by funding round
DateStageValuation
Jun 2020Series C$3B

Heyuan Biotechnology Funding History

Heyuan Biotechnology has raised a total of $300M across 1 funding round.

Heyuan Biotechnology funding rounds

Heyuan Biotechnology funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jun 2020Series CLoyal Valley Capital (lead); Kunlun Capital; Jinpu Investment; Sherpa Capital; Morningside; Boyuan Capital$300M$3BHeyuan Biotechnology is a biotechnology company specializing in gene therapy services, offering gene therapy vectors, gene function research, drug targets, and efficacy evaluation for basic gene therapy research. The company completed a Series C funding round on May 31, 2020, raising $300 million led by Loyal Valley Capital, with participation from Morningside and Sherpa Capital, alongside other investors including Boyuan Capital, Jinpu Investment, and Kunlun Capital. The company operates in a competitive landscape of gene therapy and biotech CRO services, with peers like Zhishan Weixin Biotechnology focusing on gene-drug R&D for genetic diseases.

Who has invested in Heyuan Biotechnology?

6 investors have backed Heyuan Biotechnology across its funding rounds, including Morningside, Loyal Valley Capital, Boyuan Capital, Kunlun Capital, Jinpu Investment and Sherpa Capital.

Lead investors include Loyal Valley Capital.


Heyuan Biotechnology Investors

Investors in Heyuan Biotechnology by funding rounds participated
InvestorHQRoundsRoleFirst check
Kunlun CapitalSingaporeSingapore1ParticipantJun 2020
Loyal Valley CapitalChinaShanghai1LeadJun 2020
Jinpu InvestmentChinaChina1ParticipantJun 2020
Sherpa CapitalUnited StatesChicago, IL1ParticipantJun 2020

This data is available for Pro users. Sign up to see all 6 Heyuan Biotechnology investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Heyuan Biotechnology Competitors

Heyuan Biotechnology competitors include listed companies like Betta Pharmaceuticals, CareDx, Veracyte and GRAIL, and private ones like ArsenalBio and Formation Bio.

Public and private companies comparable to Heyuan Biotechnology
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
ArsenalBioUnited StatesUnited StatesPrivate--$1.9B-
Formation BioUnited StatesNew York City, NYPrivate--$1B-
Betta PharmaceuticalsChinaChinaPublicly listed$538M$155M$2.9B5.5x
CareDxUnited StatesUnited StatesPublicly listed$380M($10M)$2.8B5.3x
VeracyteUnited StatesUnited StatesPublicly listed$517M$77M$3.3B4.9x
GRAILUnited StatesUnited StatesPublicly listed$147M($407M)$3.6B16.3x

Heyuan Biotechnology Public Comps

Heyuan Biotechnology is still privately-owned, but its public comps include Virbac, Neuland Laboratories, Amoytop Biotech, Regencell Bioscience, uniQure, Celldex Therapeutics, Zealand Pharma, Betta Pharmaceuticals, MBX Biosciences and Jilin Aodong.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Virbac$1.7B$325M1.9x1.8x9.9x9.0x
Neuland Laboratories$201M$61M15.0x13.1x49.3x44.6x
Amoytop Biotech$551M$193M5.5x4.7x15.6x-
Regencell Bioscience-($3M)--(923.4x)-
uniQure$16M($134M)143.6x112.7x(17.3x)(11.8x)
Celldex Therapeutics$2M($255M)1520.5x1421.3x(9.2x)(7.6x)
Zealand Pharma$1.4B$1B0.5x0.7x0.6x1.3x
Betta Pharmaceuticals$538M$155M6.0x5.5x20.9x16.8x

This data is available for Pro users. Sign up to see all Heyuan Biotechnology competitors and their valuation data.

Start Free Trial

Common questions about Heyuan Biotechnology

When was Heyuan Biotechnology founded?Heyuan Biotechnology was founded in 2013.
Where is Heyuan Biotechnology headquartered?Heyuan Biotechnology is headquartered in Shanghai, China.
Is Heyuan Biotechnology publicly listed?No, Heyuan Biotechnology is a private, VC-backed company.
What is Heyuan Biotechnology's valuation?Heyuan Biotechnology was last valued at $3B in its Series C in June 2020.
How much funding has Heyuan Biotechnology raised?Heyuan Biotechnology has raised $300M across 1 funding round.
What was Heyuan Biotechnology's last funding round?Heyuan Biotechnology's last funding round was a $300M Series C in June 2020, led by Loyal Valley Capital.
Who are Heyuan Biotechnology's investors?Heyuan Biotechnology's investors include Kunlun Capital, Loyal Valley Capital, Jinpu Investment, Sherpa Capital, Morningside and Boyuan Capital.
Which companies are comparable to Heyuan Biotechnology?Companies comparable to Heyuan Biotechnology include ArsenalBio, Formation Bio, Betta Pharmaceuticals, CareDx, Veracyte and GRAIL.

See companies similar to Heyuan Biotechnology

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial